Records containing: Membranous Nephropathy
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-23A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
-
CLINICAL_TRIALS study record update · 2026-04-16A Clinical Study on the Safety and Efficacy of CD19-Targeted Universal CAR-γδ T Cells in Relapsed/Refractory Autoimmune Nephropathy
-
CLINICAL_TRIALS study record update · 2026-03-24Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA
-
CLINICAL_TRIALS study record update · 2026-03-23An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
-
CLINICAL_TRIALS study record update · 2026-03-20PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-03-20Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2026-03-03Analysis of T- and B-Cell Subpopulations in Patients With Primary Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2026-02-18Identification of a Pharmacogenomic Signature for Anti-B Cell Precision Therapy in Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2026-02-17Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)
-
CLINICAL_TRIALS study record update · 2026-02-13Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
-
CLINICAL_TRIALS study record update · 2026-02-12A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2025-12-22Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome
-
CLINICAL_TRIALS study record update · 2025-11-18A Randomized, Controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of HLX79 (Human Sialidase Fusion Protein) in Combination With Rituximab Injection (HLX01, Anti-CD20 Antibody) Versus Placebo in Patients With Active Glomerulonephritis
-
CLINICAL_TRIALS study record update · 2025-10-14An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
-
CLINICAL_TRIALS study record update · 2025-09-11Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2025-05-09Obinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant or Rituximab-dependent Nephrotic Syndrome and in Patients Intolerant to Rituximab (the ORION Study)
-
CLINICAL_TRIALS study record update · 2025-04-24Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network
-
CLINICAL_TRIALS study record update · 2025-03-25Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy Who Failed Anti-CD20 Target Therapy
-
CLINICAL_TRIALS study record update · 2025-02-13A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
-
CLINICAL_TRIALS study record update · 2025-02-07A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
-
CLINICAL_TRIALS study record update · 2025-01-07Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis
-
CLINICAL_TRIALS study record update · 2024-11-26Evaluation of IM19 CAR-T Cell Therapy for IgA Nephropathy With Urinary Protein and Renal Dysfunction Safety and Efficacy of Patients With Primary Membranous Nephropathy and Those at Medium to High Risk Clinical Research
-
CLINICAL_TRIALS study record update · 2024-11-22A Multicenter, Randomized, Double-blinded, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy
-
CLINICAL_TRIALS study record update · 2024-05-10Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis
-
CLINICAL_TRIALS study record update · 2024-05-02An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy